Lazaros Andronis is a Lecturer in Health Economics, based in the Health Economics Unit of the College of Medical and Dental Sciences.
In the past, Lazaros has undertaken research on economic evaluations, where he assessed the cost-effectiveness of interventions in areas such as cancer and leukaemia, orthopaedics and cardiovascular disease. In addition to applied research, Lazaros has an interest in methods applicable to health economic and economic evaluation research. In 2009, he was awarded a NIHR Doctoral Research Fellowship to exploring the potential role and value of proposed analytic models as a means of assisting decisions around research funding, while, in the past he has looked into the use of sensitivity analysis and the impact of its results on coverage decisions made by the National Institute for Health and Clinical Excellence (NICE).
Lazaros Andronis joined the Health Economics Unit in 2006, shortly after he completed his MSc in Health Economics and Health Policy.
Since joining, Lazaros has worked on a number of projects, including
Trial-based economic evaluations exploring the cost-effectiveness of interventions in the areas of heart failure and orthopaedics (BRUM-CHF, DAMASK)
Single Technology Appraisals commissioned by NICE, where as a member of the independent Evidence Review Group, Lazaros assessed the manufacturer’s report on the cost-effectiveness of a pharmaceutical agent for acute and sub-acute manifestations of ulcerative colitis.
Methodology work commissioned by the NIHR Health Technology Appraisal project, to explore the current use and role of sensitivity analysis in NICE decision making
Economic evaluations of public health interventions, commissioned by the NICE Centre for Public Health Excellence to look into the cost-effectiveness of alternative options of providing public information to prevent skin cancer and cardiovascular disease
Lazaros has been successful in obtaining a NIHR Doctoral Research Fellowship. The award aims to fast-track individuals of outstanding potential early in their research careers and provides full-time funding to undertake Doctoral research. In his project, Lazaros is looking into existing analytic approaches for research priority-setting (value of information and cost-benefit (or payback) of research) with a view to determining their potential role and value in assisting research funding decisions. This project is expected to complete in October of 2012
Brealey S, Andronis L, Dale V, Gibbon A, Gilbert F and Hendry M. The effect of waiting times from General Practitioner referral to Magnetic Resonance Imaging or orthopaedic consultation for the knee on patient-based outcomes. British Journal of Radiology. In press
Bryan S, Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, Andronis L, Karnon J and Marteau T. Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice 2011; 61(591):620-627
Barton P, Andronis L, Briggs A, McPherson K and Capewell S. Effectiveness and cost-effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal 2011 28: 343
Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. (2010) A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment; 14(50):1-103.
Brealey S, Andronis L, Dennis L, Atwell C, Bryan S, Coulton S, et al. (2010) Participants' preference for type of leaflet used to feed back the results of a randomised trial: a survey. Trials; 11:116.
Ashfaq K, Yahaya I , Hyde C, Andronis L, Barton P, Bayliss S, et al. (2010) Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment; 14(54):iii-xi,
Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A, Wang D. (2010) Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technology Assessment;14 Suppl 1:9-15.
Hyde C, Bryan S, Juarez-Garcia A, Andronis L, Fry-Smith A.(2009) Infliximab for the treatment of ulcerative colitis. Health Technology Assessment; 13 Suppl 3:7-11.
Andronis L, Barton P, Bryan S. (2009) Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technology Assessment; 13 (29):iii, ix-61.
DAMASK Trial Team (Andronis L, Atwell C, Brealey S, Bryan S, Collins S, Coulton S et al.) (2008) Effectiveness of GP access to MRI of the knee: a randomised trial. British Journal of General Practice; 58(556): e1-8
DAMASK Trial Team (Andronis L, Atwell C, Brealey S, Bryan S, Collins S, Coulton S et al.) (2008) Cost effectiveness of magnetic resonance imaging of the knee for patients presenting in primary care. British Journal of General Practice 58(556): e10-16